ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2023

Abstract Number: 1058

Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

Alexandra Ladouceur1, Thomas Barnetche2, Sorilla Mary-Prey3, Caroline Dutriaux4, Emilie Gerard3, Anne Pham-Ledard3, Marie Beylot-Barry3, Maeva Zysman3, Rémi Veillon3, Charlotte Domblides5, Amaury Daste5, Marine Gross-Goupil5, Baptiste Sionneau5, Félix Lefort5, Mathieu Larroquette5, Christophe Richez6, Marie-Elise Truchetet2, Thierry Schaeverbebke7 and Marie Kostine2, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2Bordeaux University Hospital, Bordeaux, France, 3Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, 4CHU-Bordeaux, Bordeaux, France, 5Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7University Hospital of Bordeaux, Bordeaux, France

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2023

Keywords: Drug toxicity, Oncology

Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient’s own immune system to fight cancer. However, activation of the immune system often induces off-target immune-related adverse events (irAEs). ICI-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients and can lead to ICI discontinuation which might potentially negatively affect tumor outcomes. We aimed 1) to characterize the evolution of ICI-IA while ICI treatment is maintained and 2) to assess how ICI-IA influences ICI management across time.

Methods: All ICI-treated patients referred to rheumatology at Bordeaux University Hospital were identified and patients with ICI-IA defined by either the presence of at least one synovitis on physical exam and/or on imaging or polymyalgia rheumatica (PMR)-like symptoms with a follow-up of ≥ 6 months after ICI-IA onset were included. Charts were manually reviewed to extract data on baseline characteristics, investigations, management and both ICI-IA and tumor outcomes.

Results: Out of 281 referred patients, 80 fulfilled the inclusion criteria, of which 49 (61.3%) were male. The median duration follow-up after ICI-IA onset was 108 weeks [ranging from 26-330 weeks]. The most common tumor was melanoma (n=38, 47.5%), followed by lung cancer (n=16, 20.0%). The mean time from ICI-IA onset to ICI-IA treatment was 8.6 weeks and ICI was continued in 63 patients (78.8%) or temporary held in 11 (13.8%). Prednisone was prescribed in 74 patients (92.5%), csDMARDs in 22 (27.5%) and biologics in 2 (2.5%). ICI-IA resolved allowing ICI-IA treatment discontinuation in 27 patients (33.8%) while still being treated with ICI. Among those, 26 (96.3%) were treated with prednisone (median maximal dose 15 mg and median duration 52.0 weeks), 3 (11.1%) with csDMARDs and 1 (3.7%) with biologics. In patients with persistent ICI-IA while on ICI, 20 (40%) and 34 (68%) had resolved at 6 and 12 months post ICI discontinuation, respectively. During follow-up, the main reason for ICI discontinuation was a cancer stable or in remission in 31 patients (38.8%), cancer progression in 22 (27.5%), other irAE in 7 (8.8%) and ICI-IA in 4 (5.0%). Of note, ICI-IA treatment and ICI management were similar between those with active arthritis and those with resolved arthritis at 6 and 12 months post ICI discontinuation.

Conclusion: In this cohort, ICI was safely continued in most patients experiencing ICI-IA. Over one third of ICI-IA resolved despite maintaining active ICI treatment allowing arthritis treatment discontinuation. Larger studies are needed to determine predicting factors of resolving ICI-IA as this could help minimize exposure to immunosuppressive treatment.


Disclosures: A. Ladouceur: None; T. Barnetche: Eli Lilly, 2; S. Mary-Prey: Bristol-Myers Squibb(BMS), 2, 12, Congress fees participation, Merck/MSD, 2, 12, Congress fees reimbursement; C. Dutriaux: Bristol-Myers Squibb(BMS), 1, 2, 12, Clinical trials, travel and accomodation fees, Merck/MSD, 2, 12, Clinical trials, travel and accomodation fees for boards or congress, Novartis, 2, 12, Clinical trials, travel and accomodation fees; E. Gerard: Bristol-Myers Squibb(BMS), 1, 12, Clinical trials, travel to scientific meetings, Merck/MSD, 1, 12, Clinical trials, travel to scientific meetings; A. Pham-Ledard: Bristol-Myers Squibb(BMS), 12, conference participation fees, Merck/MSD, 12, Congress participation fees; M. Beylot-Barry: None; M. Zysman: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2; R. Veillon: AbbVie/Abbott, 5, Amgen, 6, AstraZeneca, 6, 12, Travel, accomodations, expenses, Bristol-Myers Squibb(BMS), 5, 5, 6, GlaxoSmithKlein(GSK), 5, Janssen, 2, Merck/MSD, 5, Novartis, 5, Roche, 6; C. Domblides: Amgen, 4, 12, travel/congress, AstraZeneca, 1, 12, travel/congress, Bristol-Myers Squibb(BMS), 1, 12, Travel/congress, Janssen, 1, Merck/MSD, 4, 12, Travel/congress, Pfizer, 12, Travel/congress, Roche, 12, Travel/congress; A. Daste: Bristol-Myers Squibb(BMS), 2, Merck/MSD, 2; M. Gross-Goupil: Amgen, 6, Bristol-Myers Squibb(BMS), 1, 6, 12, Clinical research, Merck/MSD, 1, 6, 12, Clinical research, Pfizer, 1, 12, Clinical research, Roche, 12, Clinical research; B. Sionneau: None; F. Lefort: AstraZeneca, 1, 2, 12, Clinical trials, Bristol-Myers Squibb(BMS), 12, Clinical trials, Merck/MSD, 1, 2, 12, Clinical trials, Pfizer, 12, Travel and accomodation fees, Roche, 12, Clinical trials; M. Larroquette: None; C. Richez: AbbVie/Abbott, 2, 6, Amgen, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, 12, receipt of drugs, GlaxoSmithKlein(GSK), 2, 6, Novartis, 2, 6, Pfizer, 2, 6; M. Truchetet: AbbVie/Abbott, 2, 6, Boehringer-Ingelheim, 2, 6, Gilead, 5, 6, Merck/MSD, 6, UCB, 6, 12, support for conferences; T. Schaeverbebke: AbbVie/Abbott, 1, 6, 12, Clinical trials, Bristol-Myers Squibb(BMS), 1, 1, 6, 6, Eli Lilly, 1, 5, 6, 12, Clinical trials, Janssen, 6, Merck/MSD, 12, Clinical trials, Novartis, 1, 6, 12, Clinical trials, Pfizer, 1, 5, 12, Clinical trials; M. Kostine: None.

To cite this abstract in AMA style:

Ladouceur A, Barnetche T, Mary-Prey S, Dutriaux C, Gerard E, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R, Domblides C, Daste A, Gross-Goupil M, Sionneau B, Lefort F, Larroquette M, Richez C, Truchetet M, Schaeverbebke T, Kostine M. Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/resolution-of-immune-checkpoint-inhibitors-induced-inflammatory-arthritis-while-maintaining-active-treatment-with-checkpoint-inhibitors/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resolution-of-immune-checkpoint-inhibitors-induced-inflammatory-arthritis-while-maintaining-active-treatment-with-checkpoint-inhibitors/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology